Home › Kanser sa Bato (Renal Cell Carcinoma) › Idaho
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Idaho
4 pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa mga site sa Idaho.
Mga Lungsod sa Idaho
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- at 9 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- at 3 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT03866382Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
- Saint Alphonsus Cancer Care Center-Nampa, Nampa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05327686Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Saint Luke's Cancer Institute - Boise, Boise
- Kootenai Health - Coeur d'Alene, Coeur d'Alene
- Saint Luke's Cancer Institute - Fruitland, Fruitland
- at 4 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06661720Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.